ARTICLE | Clinical News
eXIthera reports Phase I data for thrombosis candidate
November 30, 2017 11:48 PM UTC
eXIthera Pharmaceuticals Inc. (Westborough, Mass.) reported data from a Phase I trial in 60 healthy volunteers showing that thrombosis candidate EP-7041 was well tolerated with no serious adverse events reported. The company said the compound's pharmacokinetic and pharmacodynamic profile indicated "desired efficacy with minimal potential for bleeding."
Data were presented at the American Heart Association Scientific Sessions in Anaheim, Calif...
BCIQ Company Profiles
BCIQ Target Profiles